Regeneron Pharmaceuticals, Inc. (REGN) Licenses Gibson SOLA Platform to Boost R&D Efficiency

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has entered a key licensing agreement with Telesis Bio Inc. to integrate the innovative Gibson SOLA system into its laboratories. This advanced technology allows rapid, in-house DNA and gene synthesis, significantly accelerating REGN’s drug discovery timeline from several weeks to mere hours.

By using enzymatic methods to create high-precision DNA and mRNA overnight, the platform enables quicker scientific iteration, tighter IP protection, and greater independence from third-party vendors.

This collaboration reflects a growing shift in the biotech sector toward building in-house synthetic biology tools, improving data security, and supporting AI-driven drug development. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) anticipates that the platform will elevate R&D efficiency across its biologics, vaccine, and gene therapy programs.

While Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s shares have shown little movement despite successful clinical updates, analysts remain confident in its growth outlook, highlighting the long-term potential for higher earnings and stronger revenue as the benefits of this cutting-edge synthesis technology unfold.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.